Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.92 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.92 |
| ▸ | SRC | P12931 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.92 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.92 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.92 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.88 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.88 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.88 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.88 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.88 |
| ▸ | LDHA | P00338 | 1/20 | 0.88 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.88 |
| ▸ | FBP1 | P09467 | 1/20 | 0.88 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.88 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.88 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055892 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Diadenosine Tetraphosphate SCHEMBL14205963 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Diadenosine Tetraphosphate SCHEMBL849869 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL6516963 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL4357990 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL1744586 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Diadenosine Tetraphosphate SCHEMBL4363130 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Diadenosine Tetraphosphate SCHEMBL4069414 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL21067711 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL2934890 | 0.96 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013066264-A1 | ENZYMATIC SYNTHESIS OF CYCLIC AND LINEAR DIADENOSINE MONOPHOSPHATE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-05-10 | — | — | WO | claimed |
| EP-4735004-A2 | COMPOSITIONS COMPRISING STING AGONISTS AND METHODS OF USE FOR TREATING GLIOMA | Curran, Michael A. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250170159-A1 | COMPOSITIONS COMPRISING STING AGONISTS AND METHODS OF USE FOR TREATING GLIOMA | IMMUNOGENESIS INC (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025007108-A2 | COMPOSITIONS COMPRISING STING AGONISTS AND METHODS OF USE FOR TREATING GLIOMA | IMMUNOGENESIS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-117797312-A | Boston cluster trimerization state nanocluster and preparation method and application thereof | 中国科学院理化技术研究所 | 2024-04-02 | — | — | CN | disclosed |
| EP-3279663-B1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-104946705-B | A kind of method of continuous production c-di-AMP | 河南农业大学 | 2019-04-16 | — | — | CN | disclosed |
| US-10238715-B2 | Methods for treating or reducing the risk of arthritis in a subject by administering gelsolin | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2019016753-A1 | USE OF GELSOLIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INTESTINAL INFLAMMATORY DISEASES | STRONATI LAURA (IT) | 2019-01-24 | — | — | WO | disclosed |
| EP-3279663-A1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | The Brigham and Women's Hospital, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-8198094-B2 | Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100227807-A1 | Use of Gelsolin to Diagnose and Treat Inflammatory Desease (Stossel) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100049672-A1 | Methods for Reducing Sample Size of Clinical Trials | Critical Biologics Corporation | 2010-02-25 | — | — | US | disclosed |
| US-20100021428-A1 | Use Of Gelsolin To Treat Multiple Sclerosis And To Diagnose Neurologic Disease (Stossel) | BLOODCENTER RESEARCH FOUNDATION, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-2001496-A4 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2002258-A4 | USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2002258-A2 | USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES | The Brigham and Women's Hospital, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-2001496-A2 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | The Brigham & Women's Hospital, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007109056-A2 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007106577-A2 | GELSOLIN IN THE TREATMENT AND DIAGNOSIS OF NEUROLOGICAL DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170159-A1 | COMPOSITIONS COMPRISING STING AGONISTS AND METHODS OF USE FOR TREATING GLIOMA | STING1, PDCD1LG2, CGAS | P2RY1 264/4885P2RY2 112/4885SRC 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.